Prosper Trading Academy Blog

October 29, 2018

Titan Pharmaceuticals, the Trilogy

• [$TTNP](/content/titan-pharmaceuticals-the-trilogy/ "$TTNP"/index.html)
• [Biotech Stocks](/content/titan-pharmaceuticals-the-trilogy/ "Biotech Stocks"/index.html)
• [Healthcare Stocks](/content/titan-pharmaceuticals-the-trilogy/ "Healthcare Stocks"/index.html)
• [Market Commentary](/content/titan-pharmaceuticals-the-trilogy/ "Market Commentary"/index.html)
• [Mike Patton](/content/titan-pharmaceuticals-the-trilogy/ "Mike Patton"/index.html)

Titan Pharmaceuticals (TTNP) was in the news once again. After news hit the wires this morning that Canadian company Knight Therapeutics launched PROBUPHINE for treatment of opioid disorder, TTNP shares rallied over 13.2% higher pre-market. Knight has exclusive rights to distribute PROBUPHINE per an agreement with TTNP. However, TTNP shares retraced the overnight gains throughout the session. Here’s a recap of what happened.

about the author:

Mike Patton

Mike Patton took the leap into the markets beginning as a commodities broker in 2005, where he was responsible for identifying trading opportunities and executing trades on behalf of clients. After years as a broker he made the jump to education by joining the team at Trading Advantage, now Prosper Trading Academy.